<?xml version='1.0' encoding='utf-8'?>
<document id="28115222"><sentence text="Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer."><entity charOffset="29-38" id="DDI-PubMed.28115222.s1.e0" text="pyrotinib" /><entity charOffset="76-84" id="DDI-PubMed.28115222.s1.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.28115222.s1.e0" e2="DDI-PubMed.28115222.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28115222.s1.e0" e2="DDI-PubMed.28115222.s1.e1" /></sentence><sentence text="The discovery and development of a novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor SHR1258 (pyrotinib) for the treatment of HER2-postive breast cancer is presented"><entity charOffset="69-77" id="DDI-PubMed.28115222.s2.e0" text="tyrosine" /><entity charOffset="104-113" id="DDI-PubMed.28115222.s2.e1" text="pyrotinib" /><pair ddi="false" e1="DDI-PubMed.28115222.s2.e0" e2="DDI-PubMed.28115222.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28115222.s2.e0" e2="DDI-PubMed.28115222.s2.e1" /></sentence><sentence text=" The structure-activity relationship of lead series and their pharmacokinetic properties were evaluated to identify the potential candidates for further in vivo efficacy studies and preclinical safety assessments" /><sentence text=" Metabolic pathway and drug-drug interaction were also investigated in preclinical settings" /><sentence text=" In particular, major metabolites in human and animal species were assessed with regard to potential toxicity or off-target side effects" /><sentence text=" Overall, the potent and selective EGFR/HER2 dual inhibitor, pyrotinib, displayed robust anti-tumor effects on HER2-overexpressing xenograft models and sufficiently safety windows in animals as well as favorable pharmacokinetic properties in human, which substantially ensures current clinical development" /><sentence text=" Finally, recent advances of pyrotinib in clinical studies are highlighted with very encouraging outcomes in patients with HER2-postive advanced breast cancer"><entity charOffset="29-38" id="DDI-PubMed.28115222.s7.e0" text="pyrotinib" /></sentence><sentence text="" /></document>